2022. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s79. DOI:https://doi.org/10.25251/skin.6.supp.79.